Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

September 24, 2018, Fred Hutchinson Cancer Research Center
Credit: Min Yu (Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC),USC Norris Comprehensive Cancer Center

Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term. In an effort to find out why, Fred Hutchinson Cancer Research Center scientists are using a new technology to look at how cancer cells change under the pressure of immunotherapy treatments.

In a study published Sept. 24 in Nature Communications, researchers used a newly developed method for measuring molecules in single to deeply analyze the response to a combination immunotherapy for patients with Merkel cell carcinoma, a rare skin caused by a common virus.

"Twenty percent of Merkel cell patients have an initial response to immunotherapy but then relapse—it's been unclear why," said first author, Dr. Kelly Paulson, senior fellow at Fred Hutch. "Understanding the cause of relapse allows us to design immunotherapies that can get toward long-term tumor control to make cancer a more chronic disease."

Paulson and senior author Dr. Aude Chapuis, assistant member of Fred Hutch, studied cancer cells from two patients who initially responded to the combination therapy, which combined a checkpoint inhibitor to rev up the immune system with a T-cell therapy capable of zeroing in and killing the cancer cells. The T-cell therapy involves removing T cells from patients, multiplying the cells in the lab, and infusing them back into the patient.

At first the cancers shrank from the therapy.

"We saw in both patients that the cancers went almost completely away," said Paulson, who cares for patients at Fred Hutch's clinical care partner, Seattle Cancer Care Alliance. "The cancers were shrinking, and when we took biopsies we saw that the T cells actually got into the cancers and helped mediate this regression. That was exciting and the patients were doing great."

One patient improved from nearly going into hospice to returning to work, but then about two years after his T cells had been infused what looked like a bug bite appeared on his leg.

"It turned out to be metastatic Merkel cell cancer," Paulson said. "It grew quickly, it was biopsied and shortly after it showed up in multiple places."

In the second patient, the cancer returned but in an isolated spot. It's still being controlled and hasn't spread further.

In both patients, it wasn't clear why the disease had returned. In collaboration with coauthors Dr. Paul Nghiem of the University of Washington and Fred Hutch's Dr. Jason Bielas and Dr. Raphael Gottardo, the researchers used a technology called single-cell RNA sequencing to take a close look at molecular changes in T cells, tumor cells and all other cells in the tumor microenvironment to see what had changed.

"By doing this, we were able to see that the tumor was hiding specifically from the T cells," Paulson said.

The tumor was able to do this by removing one piece of a trio of genes that allow the T cells to find the cancer cells. The gene trio, human leukocyte antigens or HLA, usually all turn off or on at the same time. Traditional methods measure HLA as a group, which made the one gene being turned off undetectable. But single-cell RNA sequencing revealed that just one piece of the HLA trio had been hidden by the ; without that one piece, the came back invisible to the T cells and the tumors returned.

Paulson then wanted to see if the problem could be fixed. She cultured cells from one of the patients and applied drugs already used clinically for other cancers that turned the cancer marker back on.

Ultimately, the results could inform which combination of therapies would be used when people relapse from initial immunotherapy treatment. The researchers are testing those combinations now.

"It's absolutely revelatory," Chapuis said of the findings. "We didn't know what was going on with these and how their cancer was able to come back. Now we are able to understand what's going wrong, and that gives us a way to fix it. It's very obvious we need a multi-pronged approach rather than just one dagger that the cancer can escape."

Explore further: Triple immunotherapy for rare skin cancer shows promise in small, early-stage trial

Related Stories

Triple immunotherapy for rare skin cancer shows promise in small, early-stage trial

May 30, 2017
Three out of four patients treated with an experimental combination of three different therapies for the rare skin cancer known as Merkel cell carcinoma are in complete remission following the treatment, according to study ...

A simple blood test provides personalised therapy for cancer patients

September 6, 2018
Researchers have developed a simple blood test that can select cancer patients where therapies that use the body's own immune system (immunotherapies) are more likely to be effective.

First in-depth profile of CAR T-cell signals suggests how to improve immunotherapy

August 21, 2018
CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling ...

Often-overlooked natural killer cells may be key to cancer immunotherapy

September 10, 2018
Immune checkpoint inhibitors are revolutionizing the treatment of cancer, but new research challenges the central dogma of how these drugs work. This research, published in the prestigious Journal of Clinical Investigation, ...

Immune responses against a virus-related skin cancer suggest ways to improve immunotherapy

January 17, 2017
Researchers at Seattle's Fred Hutchinson Cancer Research Center and the University of Washington say a new study suggests ways to improve immune therapy for certain cancers including a virus-associated form of Merkel cell ...

Novel 'barcode' tracking of T cells in immunotherapy patients identifies likely cancer

February 24, 2017
A new discovery by researchers at the Fred Hutchinson Cancer Research Center in Seattle makes an important step in identifying which specific T cells within the diverse army of a person's immune system are best suited to ...

Recommended for you

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.